Trinity Biotech plc (TRIB)
After hours:
| Previous close | 1.3200 |
| Open | 1.3400 |
| Bid | 1.1200 x 1000 |
| Ask | 1.5400 x 2200 |
| Day's range | 1.3300 - 1.3800 |
| 52-week range | 0.8600 - 3.0500 |
| Volume | |
| Avg. volume | 680,266 |
| Market cap | 51.826M |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | 36.76 |
| EPS (TTM) | 0.0370 |
| Earnings date | 27 June 2022 - 01 July 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 05 June 2015 |
| 1y target est | 4.00 |
- GlobeNewswire
Trinity Biotech Announces CE Mark of its 10-Minute Covid-19 Antigen Test
DUBLIN, Ireland, May 20, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) has achieved a CE Mark for its 10-minute Covid-19 antigen test. This CE mark allows for use by healthcare professionals and trained users. The Company intends to launch the test throughout the European Union as well as other countries that recognise the CE Mark designation. In addition to its ease-of-use and impressive speed to result, in extensive clinical trails the test has demonstrated excellent 99% sensitiv
- GlobeNewswire
Trinity Biotech Announces the Successful Closing of its Strategic Investment and Partnership With The MiCo Group of South Korea
DUBLIN, Ireland, May 03, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it has closed its recently announced strategic investment with the MiCo Group. Refinancing On Tuesday, May 3, 2022, the Company successfully closed an approximately $45 million strategic investment and partnership with MiCo Ltd (“MiCo”). MiCo, a KOSDAQ-listed and Korea-based co
- GlobeNewswire
Trinity Biotech Announces Quarter 4 and Fiscal Year 2021 Financial Results
DUBLIN, Ireland, April 11, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2021 and fiscal year 2021. Fiscal Year 2021 Results Total revenues for fiscal year 2021 were $93.0m compared to $102.0m in 2020, a decrease of 8.8% year on year and were broken down as follows: Full Year2020Full Year2021Increase/(decrease
